RV, residual volume; TLC, total lung capacity.
Images courtesy of and used with permission from Jonathan Goldin, MD, PhD.
Which of the following features are present in the above axial and coronal HRCT scans?
All of these features are present in the above CT scans. Note the importance of obtaining expiratory scans to evaluate the presence of air trapping.
All of these features are present in the above CT scans. Note the importance of obtaining expiratory scans to evaluate the presence of air trapping.
Images courtesy of and used with permission from Jonathan Goldin, MD, PhD.
What is the most likely diagnosis for this patient?
While this HRCT has several features which are consistent with UIP, air trapping excludes a definite diagnosis of UIP. The predominant abnormalities and their distribution are consistent with a diagnosis of chronic hypersensitivity pneumonitis.
While this HRCT has several features which are consistent with UIP, air trapping excludes a definite diagnosis of UIP. The predominant abnormalities and their distribution are consistent with a diagnosis of chronic hypersensitivity pneumonitis.
Reprinted with permission from Mueller-Mang C et al. RadioGraphics. 2007;27(3):595-615.
Correctly identify the above images.
The image to the left is characterized by subpleural honeycombing, reticulation, and traction bronchiectasis typical of UIP. The image to the right demonstrates ground glass opacity, subpleural linear opacities, and micronodules, typical of NSIP.
The image to the left is characterized by subpleural honeycombing, reticulation, and traction bronchiectasis typical of UIP. The image to the right demonstrates ground glass opacity, subpleural linear opacities, and micronodules, typical of NSIP.
Use of this site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Policy.
Copyright © 2023, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. 01/23 / PC-US-130434
You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. site. Boehringer Ingelheim Pharmaceuticals, Inc. has not reviewed the contents of all pages and sites that may be linked to this site. Boehringer Ingelheim Pharmaceuticals, Inc. is not responsible and disclaims any liability for the content of any other page or site or for any viruses or similar harmful programs that may be present on such pages or sites. Linking to any other page or site is at your own risk.